THE US Food and Drug
Administration has expanded the
use of Opdivo (nivolumab) for
the treatment of patients with
metastatic non-small cell lung
cancer whose disease progressed
during or after platinum-based
chemotherapy.
Like Keytruda (pembrolizumab),
Opdivo targets the cellular pathway
known as PD-1/PD-L1, with the FDA
saying by blocking the pathway the
drugs may help the body’s immune
system to fight the cancer cells.
Both Opdivo and Keytruda have
been granted accelerated approval
based on a “breakthrough therapy
designation”.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Oct 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.